2 results
Approved WMORecruiting
Primary• To evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first line treatment) as measured by Progression Free Survival (PFS) in subjects with Claudin (CLDN) 18.2-positive,…
Approved WMOCompleted
Primary Objective:* The primary objective is to demonstrate the efficacy of avapritinib based on progression-free survival (PFS) determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST),…